Get the Stockscreener App
1.55
3.73%
-0.06
After Hours:
1.55
Fibrobiologics Inc stock is traded at $1.55, with a volume of 170.69K.
It is down -3.73% in the last 24 hours and up +46.23% over the past month.
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
See More
Previous Close:
$1.61
Open:
$1.6
24h Volume:
170.69K
Relative Volume:
0.81
Market Cap:
$10.32M
Revenue:
-
Net Income/Loss:
$-18.68M
P/E Ratio:
-0.2096
EPS:
-7.3948
Net Cash Flow:
$-15.70M
1W Performance:
-14.36%
1M Performance:
+46.23%
6M Performance:
-75.19%
1Y Performance:
-85.72%
1-Day Range:
$1.5206
$1.6899
1-Week Range:
$1.5206
$1.8155
52-Week Range:
$0.6201
$12.40
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.55 | 10.72M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
519.51 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.74 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.54 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
146.69 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
205.11 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications - ACCESS Newswire
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing - Yahoo Finance
FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media - Morningstar
A new patent covers a way to promote repair in damaged spinal discs from FibroBiologics. - Stock Titan
FibroBiologics ships new batch of diabetic ulce... - Pluang
FibroBiologics ships third batch of trial drug to Australia - Investing.com
FibroBiologics ships third batch of trial drug to Australia By Investing.com - Investing.com India
FibroBiologics ships a third batch of wound treatment being tested to Australia - Stock Titan
FibroBiologics regains Nasdaq bid price compliance - Investing.com
FibroBiologics Adds Sports Agent Leigh Steinberg to Board of Directors - citybiz
FibroBiologics appoints Leigh Steinberg to board By Investing.com - Investing.com Canada
Leigh Steinberg, agent behind $4B in deals, joins FibroBiologics (FBLG) board - Stock Titan
Fibro appoints Leigh Steinberg as Class II director - TradingView
FibroBiologics | 10-Q: Q1 2026 Earnings Report - Moomoo
FibroBiologics receives Australian patent for disc disease therapy By Investing.com - Investing.com Canada
FibroBiologics receives Australian patent for disc disease therapy - Investing.com
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease - Morningstar
FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment - Sahm
FibroBiologics reports cartilage repair in animal study By Investing.com - Investing.com South Africa
FibroBiologics reports cartilage repair in animal study - Investing.com
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints - PR Newswire
Armistice Capital discloses 9.99% FibroBiologics (FBLG) stake via Master Fund - Stock Titan
FibroBiologics Inc - Smartkarma
FBLG Q2 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Advances Fibroblast Pipeline - vinanet.vn
FBLG Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 7.77% Share GainEarnings Surprise Stocks - vinanet.vn
FibroBiologics receives patent for islet transplant method By Investing.com - Investing.com UK
FibroBiologics receives patent for islet transplant method - Investing.com
Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts - TradingView
FibroBiologics Patent Could Help Stretch Scarce Donor Pancreases - Stock Titan
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets - PR Newswire
FBLG Q2 2026 Earnings: Narrower Loss Beats Estimates as Pipeline AdvancesEarnings Beat Streak - vinanet.vn
FBLG Forecast & Price Target - TradingKey
FBLG Q2 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Report - vinanet.vn
Fibrobiologics Inc (FBLG) Stock News Today - TradingKey
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage - marketscreener.com
FibroBiologics patent covers Sox9 turning fibroblasts into cartilage cells - Stock Titan
H.C. Wainwright cuts FibroBiologics price target to $6 on model adjustments - Investing.com
FibroBiologics Faces Material Clinical Trial and Regulatory Risks That Threaten Commercialization Timeline and Long-Term Outlook - TipRanks
FibroBiologics, Inc. Revenue Breakdown – NASDAQ:FBLG - TradingView
FBLG: Advanced clinical pipeline, reduced R&D costs, raised $12M, and expanded patent assets - tradingview.com
FibroBiologics Q2 EPS beats estimates as losses narrow 72.5% - scanx.trade
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate - PR Newswire
FIBROBIOLOGICS ($FBLG) Releases Q2 2026 Earnings - Quiver Quantitative
FibroBiologics, Inc. 2Q 2026: Net loss $(4.12M), EPS $(0.66) — 10-Q Summary - TradingView
FibroBiologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form DEF 14A FIBROBIOLOGICS For: 31 July By Investing.com - Investing.com Nigeria
FBLG Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage ContinuesEarnings Decline Risk - vinanet.vn
FBLG Q1 2026 Earnings: EPS Misses Slightly as Pre‑Revenue Biotech Continues R&D FocusForward EPS Estimate - vinanet.vn
Fibrobiologics Inc (FBLG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fibrobiologics Inc (FBLG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrobiologics Inc Stock (FBLG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 03 '26 |
Buy |
0.41 |
18,200 |
7,373 |
5,942,275 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 02 '26 |
Buy |
0.35 |
17,428 |
6,152 |
5,924,075 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 04 '26 |
Buy |
0.38 |
15,872 |
6,006 |
5,958,147 |
| Davis Jason | Chief Financial Officer |
Mar 02 '26 |
Buy |
0.41 |
70,000 |
28,973 |
70,000 |
| GARCIA RUBEN A | General Counsel |
Feb 27 '26 |
Buy |
0.33 |
40,000 |
13,056 |
180,000 |
| GARCIA RUBEN A | General Counsel |
Dec 11 '25 |
Buy |
0.34 |
140,000 |
47,600 |
140,000 |
0.75%
3.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):